Fingolimod (FTY-720)

Synonyms: FTY-720A

Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.

Fingolimod (FTY-720) Chemical Structure

Fingolimod (FTY-720) Chemical Structure

CAS: 162359-55-9

Selleck's Fingolimod (FTY-720) has been cited by 22 publications

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Choose Selective S1P Receptor Inhibitors

Biological Activity

Description Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.
Targets
S1P receptor [1]
In vitro
In vitro

The main immunomodulatory mechanism of action of fingolimod is based on its effect on lymphocyte homing. It reversibly redistributes T and B cells from the circulation to secondary lymphoid organs like peripheral and mesenteric lymph nodes and Peyer's patches, thereby causing a state of peripheral lymphopenia[1].

Cell Research Cell lines NSCLC cells
Concentrations 10 μM
Incubation Time 72 h
Method

Cells were treated with various concentrations of drug for 72 h.

Experimental Result Images Methods Biomarkers Images PMID
Western blot p-myosin IIA HC / p-histone H3 S10 / Histone H3 / Cleaved TRPM7 PTEN / p53 / p-AKT / p-GSK3β / p-ERK / ERK / p-STAT3 / STAT3 / Mcl-1 / Cyclin D1 29299124
In Vivo
In vivo

SphK2 is the only enzyme which activates fingolimod in vivo,since only Sphk2 knockout mice are resistant to fingolimod-induced lymphopenia. A major advantage of fingolimod as a therapeutic agent is the possibility of its oral application. Absorption is food-independent and slow (maximal plasma concentration after 12-16 h), but extensive, and its bioavailability is high (93%). It reaches steady state concentrations after 1-2 months during daily intake. Fingolimod shows high plasma protein binding (>99.7%), mainly to albumin, and in contrast to S1P, there is no evidence for fingolimod binding to ApoM/HDL. It has a large volume of distribution of approx. 20L/kg and shows slow blood clearance (6.3±2.3 L/h), resulting in a half-life of 6-9 days[1].

Fingolimod alleviates disease burden in immune-mediated animal models of multiple sclerosis[2].

Animal Research Animal Models C57/B6 mice
Dosages 1 mg/kg
Administration o.g.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05141669 Completed Multiple Sclerosis Novartis Pharmaceuticals|Novartis May 18 2020 --
NCT03345940 Terminated Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4

Chemical lnformation & Solubility

Molecular Weight 307.47 Formula

C19H33NO2

CAS No. 162359-55-9 SDF --
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 13 mg/mL ( (42.28 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fingolimod (FTY-720) | Fingolimod (FTY-720) ic50 | Fingolimod (FTY-720) price | Fingolimod (FTY-720) cost | Fingolimod (FTY-720) solubility dmso | Fingolimod (FTY-720) purchase | Fingolimod (FTY-720) manufacturer | Fingolimod (FTY-720) research buy | Fingolimod (FTY-720) order | Fingolimod (FTY-720) mouse | Fingolimod (FTY-720) chemical structure | Fingolimod (FTY-720) mw | Fingolimod (FTY-720) molecular weight | Fingolimod (FTY-720) datasheet | Fingolimod (FTY-720) supplier | Fingolimod (FTY-720) in vitro | Fingolimod (FTY-720) cell line | Fingolimod (FTY-720) concentration | Fingolimod (FTY-720) nmr